Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
I agreed with you 100%. BUY GRCV **************************
GRCV is oversold, undervalued.
Go GRCV ***************************
I'm long and holding GRCV.
0.0002 is almost gone,0.0003 is about to begin.
The chart technical analysis, BOLLINGER BANDS , also says that: "About to initiate a NEW trend".
http://investorshub.advfn.com/boards/read_msg.aspx?message_id=110429564
With a SMALL float of 710,032,474 GRCV will move up to 0.0003 easily and then 0.0004 and higher.
http://investorshub.advfn.com/boards/read_msg.aspx?message_id=110426989
Go GRCV ******************************
Was going to add more but will wait till 2s fall off some one has an endless supply
GRCV technical analysis:PRICE TARGETS/NEW TREND begins:
http://www.allotcbb.com/quote.php?symbol=GRCV
Technical Analysis SAYS:
GRCV 52wks low = 0.0001
GRCV 52wks high= 0.013
Six(6) months price target = 0.0073
One(1) year price target = 0.0117
RSI: OVERSOLD.
Bollinger Bands say: About to initiate a NEW TREND.
Go GRCV *********************
GRCV is undervalued. Go GRCV **************************
GRCV is a good MARIJUANA stock to buy and hold.
Go GRCV *************************
MJ Oregon NEWS, MJ Oregon NEWS, MJ Oregon NEWS:
http://www.bendbulletin.com/localstate/2789375-151/oregon-lawmakers-busy-filing-marijuana-bills
Oregon passed its MJ law on 11/4/2014 and this NEW MJ law will take effect THIS July 2015, marijuana legalization for recreational uses in Oregon begins THIS July 2015.
http://www.otcmarkets.com/otciq/ajax/showNewsReleaseDocumentById.pdf?id=13069
Oregon is the RIGHT MARIJUANA state for GRCV.
GRCV stock will pop and fly into multiple penny land BECAUSE GRCV marijuana farm is located in Bend, Oregon.
GRCV is a good marijuana stock and is a strong buy.
Marijuana legalization is REAL, is here to stay!
Go GRCV ********************************
Decent buy here for a Friday.Looks like someone sees
potential.I think patience will pay on this one.Looking to add
on Monday to my position.Have a fantastic weekend all!
GRCV Wrap-Up:
you have nothing to lose now.
It's already the worst it can be from it's .007 day.
To sellers: You only lose if you sell.
It's better to just put it away and come back later.
Selling 2's doesn't do anything for you.
It can only go up from here, but needs a reason.
. That's the math.
The Dow can lose 1000 points and we'll still be at .0002.
If someone with an outstanding background
suddenly comes into the picture then this 'will' move.
OR, if the company really wants transparency and posted
updated pix of the $3,000,000 server room
with the address, then this will move.
Until then... it's just ' once upon a time, there
was a $3 million dollar no address server room'. :(
That's the math...
Dow selloff today. Was afraid GRCV would go down....oh it's already own.
Totally amazing that there are so many shares on bid/ask and nothing is trading. 154M+ on the bid & nearly 39M on the ask. Looks like bidders/sellers want more than .0001 to sell and ask's/buyers want less than .0002 to buy in and is most likely the reason why no executions are going through, any comments? GLTA
HCIT
GRCV will pop and will fly into penny land.
GRCV is a marijuana stock. MJ legalization is real, is here to stay.
GRCV is a strong buy, imo.
Go GRCV ***************************
GRCV is a good MARIJUANA stock and undervalued.
Go GRCV *************************
.0002 should fall soon too much potential here with the MJ acquisition coming. MJ hasn't really broken out but more and more states are beginning to approve MJ for the revenue potential for both the retailer the producer and related ancillary businesses and not to forget the tax revenue for states. It's not if but when it will expand in the US>.
MARIJUANA FARM, MARIJUANA FARM, MARIJUANA FARM in OR.
http://www.otcmarkets.com/otciq/ajax/showNewsReleaseDocumentById.pdf?id=13069
GRCV is in the FINAL stages of negotiations with a MARIJUANA GROW FARM in Bend, Oregon.
INFORMATION about the marijuana grow farm in Bend, Oregon:
http://investorshub.advfn.com/boards/read_msg.aspx?message_id=110233384
Oregon is the RIGHT state for GRCV because OR has legalized MARIJUANA for RECREATIONAL uses in Nov 2014.
GRCV is a good MJ stock to buy, imo.
Marijuana legalization is REAL, is here to STAY!
Go GRCV ******************************
GRCV's 52wks low/ 52wks high, SS, revenues, assets:
1)
http://data.cnbc.com/quotes/grcv
52wks low= 0.0001 on 1/29/2015.
52wks HIGH = 0.013 on 12/12/2014.
2)
GRCV is OVERSOLD and is undervalued, Its market value is only $350,000.
while its assets is $2,445,647.97.
3)
GRCV o/s = 1,750,020,071 shares (SMALL o/s comparing to other MJ stocks).
GRCV float = 710,032,474. shares (small float)
4)
GRCV Q3 revenue = $189,214.90 (Big revenue comparing to other MJ stocks)
GRCV Q3 profit = $8,000.71 (It's hard to find a MJ company with profit)
GRCV assets = $2,445,647.97 (BIGGER than its market value of $350,000. Therefore, GRCV is undervalued).
5) COMPARING to ERB*(MJ stocks comparisons):
ERB* O/S= more than 4,000,000,000. shares (more than 4BL shares while GRCV O/S is only 1,750,020,071. shares).
ERB* Q3 revenue is only $60,111. (Smaller than GRCV Q3 revenue)
ERB* pps = 0.0133, ERB* market value= MORE than $50,000,000.
6) CONCLUSION: GRCV is VERY undervalued.
GRCV is good MARIJUANA stock to buy, imo.
Marijuana legalization is REAL, is here to stay.
Go GRCV ************************************
Now they can smoke their latest investment while withdrawing shares. :(
You are assuming they intend to actually do anything other than sell shares for a living.
I admit I am not too sure about the otcexchange.info yet
until I see income producing features.
When I mentioned the 10 acre marijuana farm for sale posted from last month
on Craigslist the seller indicated several things about the
property and that it can be bought for $4000 down, total price of $55k for 10 acres.
No current crop but zoning okay for marijuana.
My math would say this is their best bet for an easy entrance into mmj.
This may happen.
Another GREAT post. GO GRCV ********************
http://investorshub.advfn.com/boards/read_msg.aspx?message_id=110179057
GREAT POST. Go GRCV *********************************
http://investorshub.advfn.com/boards/read_msg.aspx?message_id=109026870
I've been following this group since 2010 to expose the scams they are running
You're right owning this would be insane at .007 and now bottom fishers are here.
All these sub pennies have a lot of nice words that don't mean
anything until they actually show a profit from something...the same with GRCV.
This stock has a lot of loose ends, more questions than answers.
I'm curious, you can't short a .0002 stock and you're not buying,
so why spend your time here?
Your inputs seem a bit smarter than most who post here too.
Other than Janice, she's the adult supervision here also asking the right questions.
How is this not spam? It's like all your posts just repeat themselves? ?? wth??? Are you just trying to help the dump? How much you wanna bet once these 36M in 2's are done we see another 50M come through?
MARIJUANA FARM: GRCV is in the FINAL stages of negotiations with a MARIJUANA FARM located in Bend, Oregon.
http://www.otcmarkets.com/otciq/ajax/showNewsReleaseDocumentById.pdf?id=13069
Oregon is the RIGHT state for GRCV because Oregon has legalized MARIJUANA for RECREATIONAL USES in Nov 2014.
Information about MARIJUANA FARM in Bend, OR:
http://investorshub.advfn.com/boards/read_msg.aspx?message_id=110233384
Marijuana legalization is REAL, is here to stay!
GRCV is UNDERVALUED.
GRCV is a strong BUY, imo.
Go GRCV ******************************
GRCV SS(Small float), PRICE TARGETS, COMPARISIONS:
http://investorshub.advfn.com/boards/read_msg.aspx?message_id=110262061
Go GRCV ******************************
Can someone post the Lvl 2 ? Any MM manipulation over here ? This stock is embarrassing right now.
Awe hell I didn't buy any 007s - that would have been insane.
You aren't very familiar with MZ are you?
It's easy to see who lost money here from when the stock was .007.
But I do admit your logic makes sense.
Yup, watch for a BILLION dump day sometime soon as they are obviously handing out the conversion shares..........which by the way never actually attack the principal.........THAT'S WHY ITS CALLED DEATH SPIRAL FINANCING....... or in layman's terms - Money Laundering
Massive dilution/dumping ???
Jmho
GRCV MARIJUANA FARMS and other news:
http://investorshub.advfn.com/boards/read_msg.aspx?message_id=110328879
WHAT IS THE NEXT FLUFF PR IN CEO'S HAT
MAY BE BUYING APPLE TO GET THEIR IPHONE BUINESS LOL LOL
JMHO
BUY NOW or regret later. GRCV is UNDERVALUED!
People are BUYING GRCV.
GRCV will pop and will fly into multiple penny land.
BUY NOW or regret later!
GRCV is UNDERVALUED!
Go GRCV ********************
Please read this all the way to the bottom Marijuana Stocks 2015: What You Need to Know
By Todd Campbell | More Articles
January 20, 2015 | Comments (2)
Both medical and recreational marijuana have been in the news over the past year, with changes in both social acceptance and legal status in different parts of the country. Tune in to learn what investors should know when looking at marijuana-related stocks.
This health care edition of Industry Focus looks at what it actually means to invest in marijuana stocks in today's market, what investors should keep in mind, and how the two leading medical marijuana companies stack up.
Michael Douglass: Marijuana stocks in 2015. This is Industry Focus.
[INTRO]
Hi Fools, health care analyst Michael Douglass here today. The topic of the day is going to be marijuana stocks. I've got Todd Campbell on hangouts with us, from New Hampshire. Todd, how are you doing?
Todd Campbell: I'm doing really well. I remembered to wear my green shirt today.
Douglass: That's important. We actually didn't match this time, which is a shame. We do about half the time. I guess my people will call your people. We'll make sure that happens more in the future, all right?
All right, sounds good. One of the things that biotech investors, health care investors -- heck, general retail investors -- are really interested in is marijuana stocks, particularly because we've got some marijuana stocks with some incoming catalysts in 2015 and 2016. We wanted to spend a little bit of time talking about them and looking at their opportunities, and what we think about them as stocks.
Let's start with the granddaddy in the field which is, I think we have to say, GW Pharma (NASDAQ: GWPH ) . They are the name that is always on the tip of somebody's tongue when we're talking about cannabidiol or marijuana stocks. Todd, what's your take?
Campbell: Marijuana stocks caught a lot of attention last year. I think part of that was because of the election cycle. There were some pretty key elections that were going on, that were addressing both expanding medical marijuana, and also there was some recreational marijuana legislation that was being voted on last fall as well.
Overall in the marijuana space, as you mention GW Pharma is one of only two that I would define as being investable marijuana stocks. By "investable" I mean that they're widely traded on major exchanges.
Anybody who watched "The Wolf on Wall Street" knows that you should probably avoid pink sheet stocks.
Douglass: Yes!
Campbell: That's where a lot of these marijuana stocks outside of GW Pharma and Insys Therapeutics (NASDAQ: INSY ) tend to trade. We tend to focus here on more widely traded stocks. They're more proven than some of these others.
Last year you had GW Pharma and Insys, both of them returned about 64% on the year, a really big showing for those two companies. That excitement centered mainly around both of the companies' work on basically taking the chemical compounds that are found in marijuana, synthesizing those, and then delivering those to patients to try and help indications that really have an unmet need.
For example, GW Pharma has been studying its drug Sativex for use in cancer pain. It's also been studying CBD for use in epilepsy. In 2015, GW Pharma is going to roll out more data that investors will be able to dissect and digest, to see whether or not they want to be long the stock heading into the 2016 election year cycle.
Personally, I'm not a huge fan of GW Pharma for 2015 because I think that the stock run last year may have made it a little bit pricy.
Douglass: Yes, I think that's a fair concern. Traditional valuation is a little tough in health care because earnings per share, as shown by a number of stocks, those can quadruple one year on another.
But when you look at their price to sales, for example, for the trailing 12 months, it's 33 according to Yahoo! Finance. That is a pretty substantial ... that's priced to perfection, and I think that there are a couple of concerns there.
For me, one of the big ones is there's an election that says, "We're legalizing marijuana in X state," and immediately the so-called marijuana stocks get affected, even though these are really going through the FDA. It's a biotech cannabidiol. It's not really what you traditionally think of as marijuana, A.
Then B, there's also this recent Sativex Phase III trial in cancer pain, in which Sativex -- a GW drug -- basically failed to beat placebo. Now of course, this is the first of three Phase III trials there, but I think it's a little bit of a concern for investors who have just priced this stock so high.
Campbell: Michael, that's an awesome point because what it does is it really points to what it is that an investor is trying to accomplish with buying marijuana stocks. I think that a lot of people are looking at it and saying, "Look what happened to people who invested in alcohol after prohibition ended," or "Look at how big the market is for tobacco products. Could marijuana be that big someday?"
Unfortunately, right now there's no real companies that you can invest in, in the stock market, that are handling the legal cannabis side of things.
Douglass: Right.
Campbell: GW Pharma and Insys, to your point, they're researching synthetic drugs that are based on the chemical components of marijuana. Those are going to have to go through FDA trials, prove themselves through those trials, and get approved.
In the case of Sativex, they were unable to beat placebo in the first of the three Phase III trials that are going to give us data readouts this year. That's not a ringing endorsement.
What it does is it reminds me of what happened 10-15 years ago with tobacco. There was a lot of interest in developing treatments or medicine based on tobacco, that ended up going nowhere because when push came to shove, clinical trials couldn't show the efficacy could outperform anything else.
Douglass: Right. When it comes down to any biotech stock data is key, and so far in this particular indication Sativex data hasn't been good. Now of course, could it have good data in this indication in these other Phase III trials? Could it have good data in other indications? Of course.
But when you have a stock that's priced this richly, I think you have to have perfect execution, just about, to justify that valuation. I think that's a very legitimate concern for Foolish, relatively risk-averse investors to have.
Now, let's turn the conversation over to Insys. This is a stock you're a little bit more bullish on than GW Pharma. What's your elevator pitch for it?
Campbell: Insys is an intriguing company. It's more intriguing to me than GW Pharma because it's already generating revenue. It already has a product on the market. It markets a drug called Subsys. Subsys is an opiate spray that's used to treat breakthrough cancer pain, and it's been a really big success.
Sales of the drug doubled in the most recently reported quarter, the third quarter, to about $58 million. It's a drug that's already doing about $230-240 million a year. Insys has the same market cap as GW Pharma, that doesn't have any revenue aside from Sativex is approved for MS spasticity in Europe, and maybe they get $5-6 million a year in sales from that.
I think Insys has proven itself. It has revenue that's giving it financial flexibility. That financial flexibility means that it's debt-free, there's less chance of dilution, and it has plenty of money that it can reinvest into its own marijuana research programs, which are studying CBD also for epilepsy.
Many GW Pharma investors would argue that epilepsy is the reason to own GW Pharma. I would say that Insys has the same opportunity, but it has better financials.
Douglass: Yes, and when you look at that revenue differential -- again, just quoting Yahoo! Finance -- GW Pharma's is under $50 million for the trailing 12 months, and Insys' is right around $200 million, so you have the same valuation on 4x the sales. Okay, that may be a better opportunity for folks.
You can see that difference in that price to sales ratio -- it's only 8, for instance -- which I know is still rich by most valuations, but in biotech it's not really that far off the beaten path.
Campbell: Yes. For full disclosure, I happen to long Insys, so I want to make sure that people are aware of that.
Douglass: Sure.
Campbell: One of the other things that I think investors need to be watching for in Insys is that the early stage research for epilepsy drugs is intriguing, but they have a much closer catalyst in their oral new formulation of the long-standing marijuana drug Marinol, which of course has been used for 20-some odd years to help reduce chemotherapy-induced nausea.
They have what they think is a better mousetrap for that marijuana drug. It's a $150 million market that's growing 4% a year. They think they can capture a lot of that market if they can win FDA approval.
They've had some hiccups as far as their filing of information with the FDA, but supposedly that's going to get filed this quarter, which could clear the way for an approval and have it go on market sometime early in '16.
Douglass: Sure. I'll say again, looking at it from a valuation perspective and from a potential growth perspective, Insys is not -- me personally -- my style of investing. But again, one of the nice things about The Motley Fool, we're motley!
We definitely have differing viewpoints on companies, and we believe that an open and free marketplace of ideas about them is going to make us all better investors, so I think it's really important for us to have disagreements.
For me, when I look at that market size and the potential growth, it looks too rich for me. I still worry about the association with marijuana bump, getting people unreasonably excited, catalysts that have nothing to do with the business -- like marijuana legalization in a certain state bumping the stock for no reason.
That's the sort of thing that always concerns me, and it's a worry for me going forward for the business. But I will say, if you're really interested in the space and you're putting your money somewhere, I would definitely prefer Insys to GW. I like their opportunities better.
Campbell: Yes, I think you make a great point as far as, investors generally speaking have not done well chasing fads or whatever's in the news for the moment.
You need to approach these things not through rose-colored lenses, but you need to do your homework, your due diligence, and you need to be willing to admit when you're wrong, especially when it comes to investing in biotechnology companies.
The reality is that 90% of drugs fail in clinical trials, so the odds are kind of stacked against you in that regard. You need to be willing to say, "I'm willing, after doing my homework, to take on the risk of being completely wrong."
Douglass: Yes, that is part of the deal. Certainly one thing we're all about here at The Motley Fool is educating people and making sure that they have the data they need to make smart decisions.
Todd, thank you for your thoughts on marijuana stocks today. I think this has been a really good conversation, and one that I think is going to be ongoing since we always seem to talk about them a little bit, on- and off-camera!
Let's definitely circle back up on this, especially once data is out from our friends at the J.P. Morgan conference this afternoon on Insys. That will be very interesting. Until then folks, stay tuned to Fool.com and the Industry Focus podcast for all of your investing needs, and Fool on!
Todd Campbell has no position in any stocks mentioned. The Motley Fool owns shares of JPMorgan Chase. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.
The Next Industry To Crumble...
Imagine owning Amazon.com (up over an insane 4,000% since 2001) when Internet sales rendered big-box retailers obsolete...
Or Apple (up over a mindboggling 6,000% since 2004) when smartphones made landlines irrelevant.
Now an industry 99% of us use daily is set to implode... And 3 established companies are perfectly positioned to take advantage of this game-changing economic shift. That's why I urge you to click below to find out which industry is going the way of the dinosaur... and how YOU can take advantage.
Click to see the stunning presentation.
Read/Post Comments (2) | Recommend This Article (3)
Email Print Feedback 9
Email Print
Comments from our Foolish Readers
Help us keep this a respectfully Foolish area! This is a place for our readers to discuss, debate, and learn more about the Foolish investing topic you read about above. Help us keep it clean and safe. If you believe a comment is abusive or otherwise violates our Fool's Rules, please report it via the Report this Comment Report this Comment icon found on every comment.
Report this Comment On January 28, 2015, at 11:21 PM, SELLmtg wrote:
GRCV is in the FINAL stages of negotiations with a MARIJUANA FARM in Bend, Oregon (Source: otcmarkets.com, type in GRCV, Click on "News", Read the 1/8/15 news).
GRCV=0.0002 and will go up higher. GRCV is a strong buy.
Report this Comment On January 28, 2015, at 11:41 PM, SHEEPSKAPE wrote:
TRTC is a unmitigated disaster. Massive pending Dilution through toxic financing.
-167
$HEEP
Add your comment.
Your Fool username will be displayed with your comment.
Please be respectful with your comments. Review our Fool's Rules.
Your comment may be delayed up to 15 minutes
Compare Brokers
E*TRADE
Open Account
TD Ameritrade
Open Account
Sharebuilder
Open Account
Fidelity
Open Account
Fool Disclosure
Sponsored Links
Leaked: Apple's Next Smart Device
(Warning, it may shock you)
The secret is out... experts are predicting 458 million of these types of devices will be sold per year. 1 hyper-growth company stands to rake in maximum profit - and it's NOT Apple. Show me Apple's new smart gizmo!
I was about to say the same thing. 50 million shares snapped up @.0002. I hope this is the beginning of something big.
GRCV MARIJUANA FARM, MARIJUANA FARM.
GRCV is in the FINAL stages of negotiations with a MARIJUANA FARM located in Bend, Oregon.
http://www.otcmarkets.com/otciq/ajax/showNewsReleaseDocumentById.pdf?id=13069
Information about the MARIJUANA FARM in Bend, Oregon.
http://investorshub.advfn.com/boards/read_msg.aspx?message_id=110233384
Oregon is the RIGHT state for GRCV because Oregon has legalized MARIJUANA for RECREATIONAL uses in Nov 2014.
GRCV is UNDERVALUED.
GRCV is a strong buy, imo.
Go GRCV ******************************
I see many OTC releases
Otcexchange then some mj stuff then software acquisition ???
What does this co do actually other then selling shares???
Jmho
Question to the board.
Why this co puts out news in OTC not any wire. Isnt it a big deal with otcexchange.info site and what it can provide. If genuine why not let the investment community know in ä big way.
Is this a scam ??
Jmho
Unusual increase in buying today. Does anyone know something?
All speculation on what they are doing and cause of the selloff. What's important now is L2 see if we can break through main resistance .0003 then things will start to improve.
agree lukin4winners
For a company that wants to promote company transparency.
they would do well explaining what happened on the Dec23rd sell off.
The fact that it's not addressed concerns me.
Then they keep adding projects (mms farm and trading software)
from other directions before getting the primary task up and going.
What I don't like on the mmj farm is no income details, and not real details.
what I don't like about the trading software is that it sounds like they picked it up at a bankruptcy auction.
That may be good, it may be great...I don't know.
Followers
|
257
|
Posters
|
|
Posts (Today)
|
36
|
Posts (Total)
|
27669
|
Created
|
05/31/07
|
Type
|
Free
|
Moderators BeachBum Penny Stocks 2.0 |
Volume | |
Day Range: | |
Bid Price | |
Ask Price | |
Last Trade Time: |